Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
لماذا يهم هذا الخبر؟
سيظهر الملخص التحليلي هنا بعد اكتمال معالجة الذكاء الاصطناعي.
سياق الخبر
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
فتح الخبر الأصلي